免疫治疗在EGFR突变非小细胞肺癌中的研究进展

Advances in immunotherapy in EGFR-mutated non-small cell lung cancer

表皮生长因子受体酪氨酸激酶(epidermal growth factor receptor,EGFR)驱动基因突变的非小细胞肺癌患者,使用EGFR抑制剂(epidermal growth factor receptor inhibitors,EGFR-TKIs)是标准治疗模式,但获得性耐药不可避免。对于一线EGFR-TKIs耐药的非小细胞肺癌(non-small cell lung cancer,NSCLC)患者,目前没有标准的治疗方式。免疫治疗联合含铂双药化疗、血管内皮生长因子(vascular endothelial growth factor,VEGF)抑制剂的治疗模式显示出了一定的疗效。本文通过综述不同程序性死亡蛋白1(programmed cell death 1,PD-1)/PD-1配体(PD-1 ligand,PD-L1)免疫检查点抑制剂在EGFR突变的NSCLC患者的研究现状,并探讨针对EGFR突变的NSCLC患者更加合适的治疗方式。

In patients with non-small cell lung cancer(NSCLC)with EGFR driver mutation,EGFR-TKIs is the standard treatment but acquired resistance is inevitable.There is currently no standard treatment for first-line EGFR-TKIs-resistant NSCLC patients.Im⁃munotherapy combined with platinum-containing double-drug chemotherapy and vascular endothelial growth factor inhibitors has shown some efficacy.This paper reviews the research on different programmed cell death 1(PD-1)/PD-1 ligand(PD-L1)immune checkpoint inhibitors in the treatment of NSCLC patients with EGFR mutation,and explores improved treatment modalities for NSCLC patients with EGFR mutation.